Skip to main content
SpringerLink
Log in

Immunotherapy of human solid tumours: principles of development

  • Chapter
Immunological Aspects of Cancer

Abstract

Immunotherapy has emerged during the 1970s as a promising and important new modality in the strategy of cancer treatment. While immunotherapy is still in its infancy and still largely empirical in design, there have been enough significant clinical benefits to justify optimism that this therapeutic modality will take its place alongside surgery, radiotherapy and chemotherapy as a major approach in the management of cancer patients during the next decade.

Supported by Contract NOl-CB-33888 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014. Drs Gutterman and Mavligit are the recipients of Career Development Awards (CA71007-04 and CA 00130-04, respectively) from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014, USA

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klein, G. (1975). The Bertner Foundation Memorial Award Lecture—Immunological surveillance against tumors. In: Immunological Aspects of Neoplasia. The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas, p. 25. (Baltimore, Md.: The Williams & Wilkins Company)

    Google Scholar 

  2. Hersh, E. M., Gutterman, J. U. and Mavligit, G. M. (1973). Immunotherapy of cancer in man. Scientific basis and current status. Monograph. (Carl Pochedly; ed.), (Springfield, 111.: Charles C. Thomas, Inc.)

    Google Scholar 

  3. Eilber, F. R. and Morton, D. L. (1970). Impaired immunologic reactivity and recurrences following cancer surgery. Cancer, 25, 362

    PubMed  CAS  Google Scholar 

  4. Alexander, P., Currie, G. A. and Thomson, M. P. (1975). The presence of soluble tumorspecific antigens in the blood of patients and experimental animals with tumors and their role in immunotherapy. In: Immunological Aspects of Neoplasia. The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas, p. 403. (Baltimore, Md.: The Williams & Wilkins Company)

    Google Scholar 

  5. Mathé, G. (1971). Active immunotherapy. Adv. Cancer Res., 14, 1

    PubMed  Google Scholar 

  6. Hersh, E. M., Whitecar, J. P., Jr., McCredie, K. B., Bodey, G. P. and Freireich, E. J. (1971). Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N. Eng. J. Med., 285, 1211

    CAS  Google Scholar 

  7. Immunopotentiation. (1973). (New York: Associated Scientific Publishers)

    Google Scholar 

  8. Howard, J. G., Biozzi, G., Halpern, B. N., Stiflfel, C. and Mouton, D. (1959). The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice of endotoxin and Salmonella enteriditis infection. Br. J. Exp. Pathol, 40, 281

    PubMed  CAS  Google Scholar 

  9. Prager, M. D. and Baechtel, F. S. (1973). Methods for modification of cancer cells to enhance their antigenicity. In: Methods in Cancer Research (H. Busch; ed.), (New York: Academic Press)

    Google Scholar 

  10. Coley, W. B. (1911). A report of recent cases of inoperable sarcoma successfully treated with mixed toxins of erysipelas and bacillus prodigiosus. Surg. Gyn. Obstet., 13, 174

    Google Scholar 

  11. Nauts, H. C., Swift, W. E. and Coley, B. L. (1946). Treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D.: reviewed in the light of modern research. Cancer Res., 6, 205

    PubMed  CAS  Google Scholar 

  12. Old, L. J., Clarke, D. A. and Benacerraf, S. (1959). Effect of bacillus calmette-guerin infection of transplanted tumors in the mouse. Nature New Biol., 18, 291

    Google Scholar 

  13. Klein, E., Holtermann, O. A., Papermaster, B., Milgrom, H., Rosner, D., Klein, L., Walder, M. J. and Zbar, B. (1973). Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. Natl. Cancer Inst. Monogr., 39, 229

    PubMed  CAS  Google Scholar 

  14. Morton, D. L., Eilber, F. R., Malmgren, R. A. and Wood, W. C. (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery, 68, 158

    PubMed  CAS  Google Scholar 

  15. Mathé, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hayat, M. and de Vassal, F. (1969). Active immunotherapy for acute lymphoblastic leukaemia. Lancet, i, 697

    Google Scholar 

  16. Bluming, A. Z., Vogel, C. L., Zeigler, J. L., Mody, N. and Kamya, G. (1972). Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann. Intern. Med., 76, 405

    PubMed  CAS  Google Scholar 

  17. Gutterman, J. U., Mavligit, G. M., McBride, C. M., Frei, E., III, Freireich, E. J. and Hersh, E. J. (1973). Active immunotherapy with BCG for recurrent malignant melanoma. Lancet, i, 1208

    Google Scholar 

  18. Morton, D. L., Eilber, F. R., Holmes, C., Hunt, J. S., Ketcham, A. S., Silverstein, M. J. and Sparks, F. C. (1974). BCG immunotherapy of malignant melanoma: summary of a seven year experience. Ann. Surg., 180, 635

    PubMed  CAS  Google Scholar 

  19. Gutterman, J. U., Mavligit, G., Gottlieb, J. A., Burgess, M. A., McBride, C. E., Einhorn, L., Freireich, E. J. and Hersh, E. M. (1974). Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and Bacillus Calmette-Guerin. N. Eng. J. Med., 291, 592

    CAS  Google Scholar 

  20. Guerin, C. (1975). The history of BCG. In: BCG Vaccination Against Tuberculosis (S. R. Rosentheal; ed.), p. 48. (Boston: Little, Brown and Company)

    Google Scholar 

  21. Mackaness, G. B., Auclair, D. J. and Lagrange, P. H. (1973). Immunopotentiation with BCG. I. Immune response to different strains and preparations. J. Natl. Cancer Inst., 51, 1655

    PubMed  CAS  Google Scholar 

  22. Gutterman, J. U., Hersh, E. M., Rodriguez, V., McCredie, K. B., Mavligit, G., Reed, R., Burgess, M., Gehan, E., Bodey, G. P. and Freireich, E. J. (1974). Chemoimmunotherapy of adult acute leukaemia: prolongation of remission in myeloblastic leukaemia with Bacillus Calmette-Guerin. Lancet, ii, 1405

    Google Scholar 

  23. Sokal, J. E., Aungst, C. W. and Snyderman, M. (1974). Delay in progression of malignant lymphoma after BCG vaccination. N. Engl. J. Med., 291, 1266

    Google Scholar 

  24. Vogler, W. R. and Chan, Y.-K. (1974). Prolonging remission in myeloblastic leukaemia by Tice-Strain Bacillus Calmette-Guerin. Lancet, ii, 128

    Google Scholar 

  25. McKneally, M. F., Maver, C. and Kausel, H. W. (1976). Regional immunotherapy of lung cancer using intrapleural BCG. Lancet, i, 377

    Google Scholar 

  26. Ribi, E. E., Meyer, T. J., Azuma, I. and Zbar, B. (1973). Mycobacterial cell wall components in tumor suppression and regression. Natl. Cancer Inst. Monogr., 39, 115

    PubMed  CAS  Google Scholar 

  27. Lederer, E., Adam, A., Ciorbaru, R., Petit, J. F. and Wietzerbin, J. (1975). Cell walls of mycobacteria and related organisms: chemistry and immunostimulant properties. Mol. Cell Biochem., 7, 87

    PubMed  CAS  Google Scholar 

  28. Yamamura, Y., Yoshizaki, K., Azuma, I., Yagura, T. and Watanabe, T. (1975). Immunotherapy of human malignant melanoma with oil-attached BCG cell wall skeleton. Gann, 66, 355

    PubMed  CAS  Google Scholar 

  29. Feund, J. (1956). The mode of action of immunological adjuvants. Adv. Tuberculosis Res., 7, 130

    Google Scholar 

  30. Weiss, D. W. (1976). M.E.R. and other mycobacterial fractions in the immunotherapy of cancer. Med. Clin. N. Amer., 60, 473

    PubMed  CAS  Google Scholar 

  31. Yamamura, Y. (1977). Immunotherapy of lung cancer with oil-attached cell wall skeleton of BCG: In:Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  32. Richman, S. P., Gutterman, J. U., Hersh, E. M. and Price, H. R. (1977). Phase I study of intratumor (TT) immunotherapy with BCG ceU wall skeleton plus P3 (CWS/P3). Proc. Amer. Soc. Clin. Oncol, Abstract 338, 351

    Google Scholar 

  33. Rapp, H. J., Kleinschuster, S. J., Leuker, D. C. and Kainer, R. A. (1976). Immunotherapy of experimental cancer as a guide to the treatment of human cancer. Ann. N., Acad. Sci., 276, 550

    CAS  Google Scholar 

  34. Currie, G. A. and Bagshawe, K. (1970). Active immunotherapy with C. parvum and chemotherapy in murine fibrosarcomas. Br. Med. J., i, 541

    Google Scholar 

  35. Milas, L., Gutterman, J. U., Basic, I., Hunter, N., Mavligit, G., Hersh, E. M. and Withers, H. R. (1974). Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum. Int. J. Cancer, 14, 493

    PubMed  CAS  Google Scholar 

  36. Reed, R. C., Gutterman, J. U., Mavligit, G. M., Burgess, M. A. and Hersh, E. M. (1975). Corynebacterium parvum: preliminary report of a Phase I clinical and immunology study in cancer patients. In: Corynebacterium parvum (B. Halper; ed.), p. 349. (New York: Plenum Publishing)

    Google Scholar 

  37. Israel, L. and Edelstein, R. (1975). Nonspecific immunostimulation with Corynebacterium parvum in human cancer. In: Immunological Aspects of Neoplasia. The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas, p. 485. (Baltimore, Md.: The Williams & Wilkins, Co.)

    Google Scholar 

  38. Israel, L., Edelstein, R., Depierre, A. and Dimitrov, N. (1975). Brief communication: daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings. J. Natl. Cancer Inst., 55, 29

    PubMed  CAS  Google Scholar 

  39. Gutterman, J., Hersh, E., Benjamin, R., Mavligit, G., Burgess, M. and Bodey, G. (1977). An effective new chemoimmunotherapy regimen for disseminated malignant melanoma (DMM). Proc. Amer. Soc. Clin. Oncol, Abstract 135, 300

    Google Scholar 

  40. Clarkson, B. D., Dowling, M. D., Gee, T. S., Cunningham, I. B. and Burchenal, J. H. (1975). Treatment of acute leukemia in adults. Cancer, 36, 775

    PubMed  CAS  Google Scholar 

  41. Ribi, E., Milner, K. C., Granger, D. L., Kelly, M. T., Yamamoto, K., Brehmer, W., Parker, R., Smith, R. F. and Strain, S. M. (1976). Immunotherapy with nonviable microbial components. Proc. N. Y. Acad. Sci., 277, 228

    CAS  Google Scholar 

  42. Carswell, W. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumor. P.N.A.S., 72, 3666

    PubMed  CAS  Google Scholar 

  43. Everall, J. D., O’Donerty, C. J., Wand, J. and Dowd, P. M. (1975). Treatment of primary melanoma by intralesional vaccinia before excision. Lancet, ii, 583

    Google Scholar 

  44. Mansell, P. W. A., Ichinose, H. and Reed, R. J. (1975). Macrophage-mediated destruction of human malignant cells in vivo. J. Natl. Cancer Inst., 54, 571

    CAS  Google Scholar 

  45. Chirigos, M. A. (ed.) (1977). Progress in Cancer Research and Therapy. Vol. 2. Control of Neoplasia by Modulation of the Immune System, p. 1. (New York: Raven Press)

    Google Scholar 

  46. Brugmans, J., Schuermans, V., De Cocr, W., Theinpoint, D., Janssen, D., Verhaegen, H., Van Nimmen, L., Louwagie, A. C. and Stevens, D. (1973). Restoration of host defense mechanisms in man by levamisole. Life Sci., 13, 1499

    PubMed  CAS  Google Scholar 

  47. Tripodi, D., Parks, L. C. and Brugmans, J. (1973). Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N. Eng. J. Med., 289, 354

    CAS  Google Scholar 

  48. Amery, W. K. (1976). Double-blind levamisole trial in resectable lung cancer. N., Acad. Sci., 277, 260

    CAS  Google Scholar 

  49. Rojas, A., Feirstein, J., Mickiewicz, E., Glait, H. and Olivari, A. J. (1976). Levamisole: clinical action in human breast cancer. Lancet, i, 211

    Google Scholar 

  50. Munder, P. G., Fischer, H., Weltzien, H. U., Oettgen, H. F. and Westphal, O. (1976). Lysolecithin analogs: a new class of immunopotentiators with antitumor activity. Proc. Am. Ass. Cancer Res., 17, 174

    Google Scholar 

  51. Zbar, B., Bernstein, I. D. and Rapp, H. J. (1971). Suppression of tumor grovnh at the site of infection with living Bacillus Calmette-Guerin. J. Natl. Cancer Inst., 46, 831

    PubMed  CAS  Google Scholar 

  52. Gutterman, J. U., Mavligit, G. M., Burgess, M. A., Cardenas, J. O., Blumenschein, G. R., Gottlieb, J. A., McBride, C. M., McCredie, K. B., Bodey, G. P., Rodriguez, V., Freireich, E. J. and Hersh, E. M. (1976). Immunotherapy of human solid tumors and acute leukemia with BCG: prolongation of disease-free interval and survival. Cancer Immunol. Immunother., 1, 99

    Google Scholar 

  53. Eilber, F. R., Morton, D. L., Holmes, E. C., Sparks, F. C. and Ramming, K. P. (1976). Adjuvant immunotherapy with BCG in treatment of regional lymph node mestastases from malignant melanoma. N. Engl. J. Med., 294, 237

    PubMed  CAS  Google Scholar 

  54. Gutterman, J. U., Cardenas, J. O., Blumenschein, G. R., Hortobagyi, G., Livingston, R. B., Mavligit, G. M., Freireich, E. J., Gottlieb, J. A. and Hersh, E. M. (1976). Chemoimmunotherapy of disseminated breast cancer: prolongation of remission and survival. Br. Med. J., ii, 1222

    Google Scholar 

  55. Whittaker, J. A. and Slater, A. J. (1977). The immunotherapy of acute myelogenous leukemia using intravenous BCG. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  56. Sokal, J. E., Aungst, C. W., Snyderman, M. and Gomez, G. (1976). Immunotherapy of chronic myelotic leukemia: effects of different vaccination schedules. Ann. N. Y. Acad. Sci., 277, 367

    PubMed  CAS  Google Scholar 

  57. Mathé, G., Amiel, J. L., Halle-Pannenko, O. and Simmler, M. C. (1976). Discussion paper: experimental and clinical immunopharmacology data applicable to cancer immunotherapy. Proc. N. Y. Acad. Sci., 111, 467

    Google Scholar 

  58. Bliznakov, E. H. (1977). Immunostimulation or immunodepression? Biomedicine, 26, 73

    PubMed  CAS  Google Scholar 

  59. Rook, G. A. W. (1975). The immunological consequences of antigen overload in experimental mycobacterial infection of mice. Clin. Exp. Immunol., 19, 167

    PubMed  CAS  Google Scholar 

  60. Verhaegen, H., Verbruggen, F., Verhaegen-Decloercq, M. L. and De Cree, J. (1974). Effets du levamisole sur les reactions cutanees d’hypersensibilite retardee. La Nouv. Presse Med., 9, 2483

    Google Scholar 

  61. Bekesi, J. G., Roboz, J. P. and Holland, J. F. (1976). Therapeutic effectiveness of neuraminidase treated tumor cells as an immunogen in man and experimental animals with leukemia. Ann. N., Acad. Sci., 111, 313

    Google Scholar 

  62. Lindenmann, J. (1973). The use of viruses as immunological potentiators. In: Immunopotentiation. p. 297. (New York: Associated Scientific Publishers)

    Google Scholar 

  63. Reisfeld, R. A., Pellegrino, M. A. and Kahan, B. B. (1971). Salt extraction of soluble HLA antigens. Science, 172, 1134

    PubMed  CAS  Google Scholar 

  64. Graham, J. B. and Graham, R. M. (1962). Autogenous vaccine in cancer patients. Surg. Gyn. Obstet., 114, 1

    CAS  Google Scholar 

  65. Powles, R. L., Balchin, L. A., Hamilton-Fairley, G. and Alexander, P. (1971). Recognition of leukaemia cells as foreign before and after autoimmunization. Br. Med. J., 1, 486

    PubMed  CAS  Google Scholar 

  66. Ezaki, K., Hersh, E., McCredie, K., Hollinshead, A., Dyre, S., Mavligit, G. and Gutterman, J. U. (1971). Active specific immunization in acute leukemia. Proc. Am. Ass. Cancer Res., 18, No. 996, 242

    Google Scholar 

  67. Bekesi, J. G., Holland, J. F., Cuttner, J., Silver, R., Coleman, M., Javowski, C. and Vincequerra, V. (1976). Immunotherapy in acute myelocytic leukemia (AML) with neuraminidase (N’ase) treated myeloblasts with or without MER. Proc. Am. Ass. Cancer Res., 17, 184

    Google Scholar 

  68. Marcove, R. C., Southam, C. M., Levin, A., Mike, A. and Huvos, A. (1971). A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five. Surg. Forum, 22, 434

    PubMed  CAS  Google Scholar 

  69. Currie, G. A. and McElwain, T. J. (1975). Active immunotherapy as an adjuvant to chemotherapy in the treatment of disseminated malignant melanoma. A pilot study. Br. J. Cancer, 31, 143

    PubMed  CAS  Google Scholar 

  70. Powles, R. L., Crowther, D., Bateman, C. J. T., Beard, M. E. J., McElwain, T. J., Russel, J., Lister, T. A., Whitehouse, J. M. A., Wrigley, P. F. M., Pike, M., Alexander, P. and Hamilton-Fairley, G. (1973). Immunotherapy for acute myelogenous leukaemia. Br. J. Cancer, 28, 365

    PubMed  CAS  Google Scholar 

  71. Townsend, C. M., Eilber, F. R. and Morton, D. L. (1976). Skeletal and soft tissue sarcomas. J. Am. Med. Ass., 236, 2187

    Google Scholar 

  72. Bekesi, J. G., Holland, J. F., Cuttner, J., Glidewell, O., Knill, R., Jarowski, C., Coleman, M. and Silver, R. (1977). Chemoimmunotherapy in acute myelocytic leukemia. Proc. Am. Ass. Cancer Res., Abstract 791, 198

    Google Scholar 

  73. Stewart, T. H. M., Hollinshead, A. C. and Harris, J. E. (1976). Immunochemotherapy of lung cancer. Ann. N., Acad. Sci., 277, 436

    CAS  Google Scholar 

  74. Woodruff, M. F. A. and Nolan, B. (1963). Preliminary observations on treatment of advanced cancer by injection of allogeneic spleen cells. Lancet, i, 426

    Google Scholar 

  75. Nadler, S. H. and Moore, G. E. (1960). Immunotherapy of malignant melanoma. Geriatrics, 23, 150

    Google Scholar 

  76. Schwarzenberg, L., Mathé, G., Schneider, M., Amiel, J. L., Cattan, A. and Schlumberger, J. R. (1966). Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet, ii, 365

    Google Scholar 

  77. Moore, G. E. and Gemer, R. E. (1975). Cancer immunity. Hypothesis and clinical trial of lymphcytotherapy for malignant disease. Ann. Surg., 172, 733

    Google Scholar 

  78. Lawrence, H. S. (1969). Transfer factor, Immunol, 11, 195

    CAS  Google Scholar 

  79. Spitler, L. E., Wybran, J., Fudenberg, H. H., Levin, A. S. and Lewis, M. (1973). Transfer factor therapy of malignant melanoma. Clin. Res., 21, 221

    Google Scholar 

  80. Oettgen, H. F., Old, L. J., Farrow, J. H., Valentine, F. T., Lawrence, H. S. and Thomas, L. (1974). Effects of dialyzable transfer factor in patients with breast cancer. Proc. Nat. Acad. Sci. USA, 71, 2319

    PubMed  CAS  Google Scholar 

  81. Alexander, P., Delorme, E. J., Hamilton, L. D. G. and Hall, J. G. (1967). Effect of nucleic acids from immune lymphocytes in rat sarcomata. Nature (London), 213, 569

    CAS  Google Scholar 

  82. Pilch, Y. H., Ramming, K. P. and Deckers, P. J. (1973). Studies in mediation of tumor immunity with ‘immune’ RNA. In: Methods in Cancer Research (H. Busch; ed.), p. 195. (New York: Academic Press)

    Google Scholar 

  83. Bloom, B. R. (1969). Elaboration of effector molecules by activated lymphocytes. In: Mediators of Cellular Immunity (H. S. Lawrence and M. Landy; eds.), p. 249. (New York: Academic Press)

    Google Scholar 

  84. Papermaster, B. W., Holterman, O. A. and Klein, E. (1976). Lymphokine properties of a lymphoid culture cell supernatant fraction active in promoting tumor regression. Clin. Immunol. Immunopathol, 5, 48

    PubMed  CAS  Google Scholar 

  85. van Bekkum, D. W. (1975). In: The Biological Activity of Thymic Hormones, p. 1. (New York: Halsted Press)

    Google Scholar 

  86. Klein, J. J., Goldstein, A. L. and White, A. (1965). Enhancement of in vivo incorporation of labelled precursors in DNA and total protein of mouse lymph nodes after administration of thymic extracts. Proc. Natl. Acad. Sci., 53, 812

    PubMed  CAS  Google Scholar 

  87. Schäfer, L. A., Goldstein, A. L., Gutterman, J. U. and Hersh, E. M. (1976). In vitro and in vivo studies with thymos in cancer patients. Ann. N., Acad. Sci., 277, 609

    Google Scholar 

  88. Wright, P. W., Hellstrom, K. E., Hellstrom, I. E. and Bernstein, I. D. (1976). Serotherapy of malignant disease. Med. Clin. N Amer., 60, 607

    PubMed  CAS  Google Scholar 

  89. Ghose, T., Norvell, S. T., Guclu, A., Cameron, D., Bodurtha, A. and MacDonald, A. S. (1972). Immunochemotherapy of cancer with chlorambucil-carrying antibody. Br. Med. J., iii, 495

    Google Scholar 

  90. Israel, L. and Edelstein, R. (1977). Increased levels of Ig A in 6 cancer sites, irrespective of extension. Proc. Am. Ass. Cancer Res., 18, 213, 242

    Google Scholar 

  91. Rosenberg, S. A. and Rapp, H. J. (1976). Intralesional immunotherapy of melanoma with BCG. Med. Clin. N. Amer., 60, 419

    PubMed  CAS  Google Scholar 

  92. Mastrangelo, M. J., Berd, D. and Bellet, R. E. (1976). Critical review of previously reported clinical trials of cancer immunotherapy with non-specific immunostimulants. Ann. N., Acad. Sci., 277, 94

    CAS  Google Scholar 

  93. Cohen, M. H., Felix, E., Jessup, J. and Rosenberg, S. (1976). Treatment of metastatic melanoma by intralesional injection of BCG, organic chemicals and C. parvum. In: Neoplasm Immunity: Mechanisms (R. G. Crispen; ed.), p. 121. (Chicago: I.T.R.)

    Google Scholar 

  94. Mastrangelo, M. J., Bellet, R. E., Berkelhammer, J. and Clark, W. H., Jr. (1975). Regression of pulmonary metastatic disease associated with intralesional BCG therapy of dermal melanoma metastases. Cancer, 36, 1305

    PubMed  CAS  Google Scholar 

  95. Mastrangelo, M. J., Sulit, H. L., Prehn, L. M., Bomstein, R. X., Yarbro, J. W. and Prehn, R. T. (1976). Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer, 37, 684

    PubMed  CAS  Google Scholar 

  96. Nathanson, L. (1972). Regression of intradermal malignant melanoma after intralesional injection ofMycobacterium bovis strain BCG. Cancer Chemother. Rep., 56, 659

    PubMed  CAS  Google Scholar 

  97. Pinsky, C. M., ElDomeiri, A., Caron, A. S., Knapper, W. H. and Oettgen, H. F. (1974). Delayed hypersensitivity reaction in patients with cancer. In:Recent Results in Cancer Research (G. Mathé and R. Weiner; eds.), p. 37–47 (New York: Springer-Verlag)

    Google Scholar 

  98. Lieberman, R., Wybfan, J. and Epstein, W. (1975). The immunologic and histopathologic changes of BCG in cell mediated tumor regression in patients with malignant melanoma. Cancer, 35, 756

    PubMed  CAS  Google Scholar 

  99. Khalil, A., Rappaport, H. and Misset, J. L. (1976). Kinetics of histologic changes in human melanoma after local immunotherapy with BCG. Cancer Immunol. Immunother., 1, 193

    Google Scholar 

  100. Hanna, M. G. Jr., Snodgrass, M. J., Zbar, B. and Rapp, H. J. (1973). Histologic and ultrastructural studies of tumor regression in inbred guinea pigs after intralesional injection of Mycobacterium bovis (BCG). Nat. Cancer Inst. Monogr., 39, 71

    PubMed  Google Scholar 

  101. Everall, J. D., O’Doherty, E. J., Wand, J. and Dowd, P. M. (1975). Treatment of primary melanoma by intralesional vaccinia before excision. Lancet, ii, 583

    Google Scholar 

  102. Gutterman, J. (1977). Malignant melanoma. In:Cancer Medicine. (In press)

    Google Scholar 

  103. Yamamura, Y., Yoshizaki, K., Azuma, I., Yagura, T. and Watanabe, T. (1975). Immunotherapy of human malignant melanoma with oil-attached BCG cell wall skeleton. Gann, 66, 355

    PubMed  CAS  Google Scholar 

  104. Richman, S. P., Gutterman, J. U. and Hersh, E. M. (1977). Phase I study of intratumor immunotherapy with BCG cell wall skeleton plus P3 (CWS/P3) (Submitted for publication)

    Google Scholar 

  105. Ikanopisov, R. L. (1975). The use of BCG in the combined treatment of malignant melanoma. In: International Symposium on Immunological Reactions to Melanoma Antigens (K. Heide; ed.), p. 206. (: Behring-Werke)

    Google Scholar 

  106. Beretta, G. (1977). Controlled study for prolonged chemotherapy, immunotherapy and chemotherapy plus immunotherapy as an adjuvant to surgery. In: Immunotherapy of Cancer: Present Studies of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  107. Pinsky, C. M., Hirshant, Y., Wanebo, J. H., Fortner, J. G., Mike, V., Schottenfeld, D. and Oettgen, H. F. (1976). Randomized trial of Bacillus Calmette-Guerin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage II melanoma. Ann. N., Acad. Sci., 277, 187

    CAS  Google Scholar 

  108. Gutterman, J. U., Mavligit, G. M., McBride, C. M., Richman, S. P., Burgess, M. A. and Hersh, E. M. (1977). Post operative immunotherapy for recurrent malignant melanoma: an updated report. In: Immunotherapy of Cancer: Present Status of Trial in Man. (New York: Raven Press) (In press)

    Google Scholar 

  109. Gutterman, J. U., Hersh, E. M., Mavligit, G. M., Burgess, M. A., Richman, S. P., Schwarz, M. A., Rodriguez, G. and Valdivieso, M. (1977). Chemoimmunotherapy of disseminated malignant melanoma with Bacillus Calmette-Guerin: follow up report. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  110. Schwarz, M. A., Gutterman, J. U., Hersh, E. M., Mavligit, G. M. and Bodey, G. P. (1977). Chemoimmunotherapy of disseminated malignant melanoma with DTIC, BCG, transfer factor ± melphalan. A.A.C.R. (Submitted for publication)

    Google Scholar 

  111. Costanzi, J. J. (1971). Chemotherapy and BCG in the treatment of disseminated malignant melanoma—a southwest oncology group study. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  112. Laucius, J. F., Bodurtha, A. J., Berkel Hammer, J., Prehn, L. M., Prehn, R. T. and Mastrangelo, M. J. (1974). Intradermal injection of autochthonous irradiated tumor cellsplus BCG in the treatment of metastatic malignant melanoma. Proc. Am. Ass. Cancer Res., 15, 849

    Google Scholar 

  113. Mastrangelo, M. J., Bellet, R. W. and Berd, D. (1977). A randomized prospective trial comparing MeCCNU X Vincrinstine to MeCCNU x Vincristine x BCG x allogeneic tumor cells in patients with metastatic malignant melanoma. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  114. Simmons, R. L. (1977). Comparison of chemotherapy plus VCN-treated autologous tumor cells in Stages II and III melanoma. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  115. Bakemier, R. F., Costello, W., Horton, J. and de Vita, V. T. (1977). BCG immunotherapy following chemotherapy-induced remissions of Stage III and IV Hodgkin’s disease. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  116. Jones, S. E., Salmon, S. E., Moon, T. E. and Butler, J. J. (1977). Chemoimmunotherapy of non-Hodgkin’s lymphoma with BCG: a preliminary report. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  117. Hoemi, B., Chauvergne, J., Hoemi-Simon, G., Durand, M. and Lagarde, C. (1977). The utility of BCG in the immunotherapy of malignant lymphomas. (Submitted for publication)

    Google Scholar 

  118. Mathé, G., Belpomme, D., Puillart, P., Schwarzenberg, L., Misset, J. L., Jasmin, C., Musset, M., Cattan, A., Amiel, J. L. and Schneider, M. (1975). Preliminary results of an immunotherapy trials of terminal leukaemic lymphosarcoma. Biomedicine, 23, 465

    PubMed  Google Scholar 

  119. Magrath, I. T. and Ziegler, J. L. (1976). Failure of BCG immunostimulation to affect the clinical course of Burkitt’s lymphoma. Br. Med. J., i, 615

    Google Scholar 

  120. Edwards, F. R. and Whitwell, F. (1974). Use of BCG as an immunostimulant in the surgical treatment of carcinoma of the lung. Thorax, 29, 654

    PubMed  CAS  Google Scholar 

  121. Ruckdeschel, J., Codish, S. D., Stranahan, A. and McKneally, M. G. (1972). Post operative empyema improves survival in lung cancer. N. Engl. J. Med., 287, 1013

    PubMed  CAS  Google Scholar 

  122. McKneally, M. G., Maver, C. and Kausel, H. W. (1977). Regional immunotherapy of lung cancer using intrapleural BCG. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  123. Pouillart, P., Mathé, G., Palangie, T., Schwarzenberg, L., Huguenin, P., Morin P., Gautier, M. and Parrot, R. (1976). Trial of BCG immunotherapy in the treatment of resectable squamous cell carcinoma of the bronchus (stages I and II). Cancer Immunol. Immunother., 1, 271

    Google Scholar 

  124. Pines, A. (1976). A 5-year controlled study of BCG and radiotherapy for inoperable lung cancer. Lancet, i, 380

    Google Scholar 

  125. Yamamura, Y., Azuma, I., Taniyama, T., Sugimura, K., Hirao, F., Tokuzen, R., Okabe, M., Nakahara, W., Yasumoto, K. and Ohta, M. (1976). Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis—Bacillus Calmette-Guerin: experimental and clinical results. Ann. N. Y. Acad. Sci., 277, 209

    PubMed  CAS  Google Scholar 

  126. Garner, F. B., Meyer, C. A., White, D. S. and Lipton, A. (1975). Aerosol BCG treatment of carcinoma metastatic to the lung: a Phase I study. Cancer, 35, 1088

    PubMed  CAS  Google Scholar 

  127. Takita, H., Takada, N., Minowada, J., Han, T. and Edgerton F. (1977). Adjuvant immunotherapy of Stage III lung carcinoma. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  128. Mavligit, G. M., Gutterman, J. U., Burgess, M. A., Khankhanian, N., Seibert, G. B., Speer, J. F., Jubert, A. V., Martin, R. C., McBride, C. M., Copeland E. M., Gehan, E. A. and Hersh, E. M. (1976). Prolongation of postoperative disease free interval and survival in human colorectal cancer by Bacillus Calmette-Guerin (BCG) or BCG plus 5-fluorouracil. Lancet, i, 871

    Google Scholar 

  129. Mavligit, G. M., Gutterman, J. U., Malahy, M. A., Burgess, M. A., McBride, C. M., Jubert, A. and Hersh, E. M. (1977). Systemic adjuvant immunotherapy and chemoimmunotherapy in patients with colorectal cancer (Dukes’ C class): prolongation of disease free interval and survival. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  130. Moertel, C. G., Ritts, R. E., Schutt, A. J. and Hahn, R. G. (1975). Clinical studies of methanol extraction fraction of Bacillus Calmette-Guerin as an immunostimulant in patients with advanced cancer. Cancer Res., 35, 3075

    PubMed  CAS  Google Scholar 

  131. Moertel, C. G., O’Connell, M. J., Ritts, R. E. Jr., Scjutt, A. J., Reitemeier, R. J., Hahn, R. G. and Frytak, S. L. (1977). A controlled evaluation of combined immunotherapy (MER-BCG) and chemotherapy for advanced colorectal cancer. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  132. Weiss, D. (1976). Discussion following presentation. Immunotherapy of cancer: present status of trials in man. National Cancer Institute, Bethesda, October 1976

    Google Scholar 

  133. Engstrom, P. F., Paul, A. R., Catalano, R. B., Mastrangelo, M. J. and Creech, R. H. (1977). Fluorouracil v. fluorouracil + Bacillus Calmette-Guerin in colorectal adenocarcinoma. In: Immunotherapy of Cancer: Present Status of Trials in Man. (New York: Raven Press) (In press)

    Google Scholar 

  134. Falk, R. E., Macgregor, A. B., Landi, S., Ambus, U. and Langer, B. (1976). Immunostimulation with intraperitoneally administered Bacillus Calmette-Guerin for advanced malignant tumors of the gastrointestinal tract. Surg. Gynecol. Obstet., 142, 363

    PubMed  CAS  Google Scholar 

  135. Donaldson, R. C. (1972). Methotrexate plus Bacillus Calmette-Guerin (BCG) and isoniazid in the treatment of cancer of the head and neck. Am. J. Surg., 124, 527

    PubMed  CAS  Google Scholar 

  136. Richman, S. P., Livingston, R. B., Gutterman, J. U., Suen, J. Y. and Hersh, E. M. (1976). Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study. Cancer Treat. Rep., 60, 535

    PubMed  CAS  Google Scholar 

  137. Eilber, F. R. and Morton, D. L. (1976). Adjuvant chemoimmunotherapy in advanced lesions of the head and neck. Am. J. Roent. Rad. Ther. Nucl. Med., 126, 1082

    CAS  Google Scholar 

  138. Townsend, C. M., Eilber, F. R. and Morton, D. L. (1976). Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy. J. Am. Med. Ass., 236, 2187

    Google Scholar 

  139. Strander, H., Cantell, K., Carlstrom, G. and Jakobsson, P. A. (1973). Clinical and laboratory investigations in man: systemic administration of potent interferon to man. J. Natl. Cancer Inst., 51, 733

    PubMed  CAS  Google Scholar 

  140. Morales, A., Eidinger, D. and Bruce, A. W. (1976). Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116, 180

    PubMed  CAS  Google Scholar 

  141. Morales, A. and Eidinger, D. (1976). Bacillus Calmette-Guerin in the treatment of adenocarcinoma of kidney, Urol., 115, 377

    CAS  Google Scholar 

  142. Merrin, C., Han, T., Klein, E., Wajsman, Z. and Murphy, G. P. (1975). Immunotherapy of prostatic carcinoma with Bacillus Calmette-Guerin. Cancer Chemother. Rep., 59, 157

    PubMed  CAS  Google Scholar 

  143. Hudson, C. N., McHardy, J. E., Curling, O. M., English, P. E., Levin, L., Poulton, T. Z., Crowther, M. and Leighton, M. (1976). Active specific immunotherapy for ovarian cancer. Lancet, ii, 877

    Google Scholar 

  144. Gutterman, J. U., Mavligit, G. M., Reed, R. C. and Hersh, E. M. (1974). Immunochemotherapy of human cancer. Seminars in Oncol., 1, 409

    CAS  Google Scholar 

  145. Gutterman, J. U. (1977). Cancer systemic active immunotherapy today-prospects for tomorrow. Cancer Immunol. Immunother., 2, 1

    Google Scholar 

  146. Farquhar, D., Loo, T. L., Gutterman, J. U., Hersh, E. M. and Luna, M. A. (1976). Inhibition of drug-metabolizing enzymes in the rat after Bacillus Calmette-Guerin treatment. Biochem. Pharmacol, 25, 1529

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. U. Gutterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Mavligit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. M. Hersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Royal Postgraduate Medical School, London, UK

    J. E. Castro

Rights and permissions

Reprints and permissions

Copyright information

© 1978 MTP Press Limited

About this chapter

Cite this chapter

Gutterman, J.U., Mavligit, G.M., Schwarz, M.A., Hersh, E.M. (1978). Immunotherapy of human solid tumours: principles of development. In: Castro, J.E. (eds) Immunological Aspects of Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-9418-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-9418-4_16

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-9420-7

  • Online ISBN: 978-94-010-9418-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation